Revolution Medicines Receives Landmark FDA Drug Approval in Pancreatic Cancer

FDA approval of Revolution Medicines’ daraxonrasib, brand name Rasonque, makes the molecule the first RAS inhibitor approved for treating pancreatic adenocarcinoma, the most common type of pancreatic cancer. The speedy regulatory nod specifically covers advanced cases of this type of cancer, which has had limited treatment options. The post Revolution Medicines Receives Landmark FDA Drug…

Read More

Why Oura’s Sleep-Tracking Lawsuit Is Really About Trust

A new class action lawsuit accuses Oura of overstating its smart ring’s sleep tracking accuracy, arguing the device relies on AI-generated estimates rather than the clinical measurements needed for true sleep staging. The case is reigniting questions about how much precision consumers should expect from AI-powered health wearables. The post Why Oura’s Sleep-Tracking Lawsuit Is…

Read More